Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Immunocore Holdings (IMCR) EBT Margin (2023 - 2025)

Historic EBT Margin for Immunocore Holdings (IMCR) over the last 5 years, with Q3 2025 value amounting to 0.29%.

  • Immunocore Holdings' EBT Margin fell 73000.0% to 0.29% in Q3 2025 from the same period last year, while for Sep 2025 it was 7.41%, marking a year-over-year increase of 107300.0%. This contributed to the annual value of 17.07% for FY2024, which is 73500.0% up from last year.
  • Latest data reveals that Immunocore Holdings reported EBT Margin of 0.29% as of Q3 2025, which was down 73000.0% from 9.9% recorded in Q2 2025.
  • Immunocore Holdings' EBT Margin's 5-year high stood at 7.59% during Q3 2024, with a 5-year trough of 594.15% in Q4 2021.
  • In the last 5 years, Immunocore Holdings' EBT Margin had a median value of 27.0% in 2023 and averaged 110.58%.
  • As far as peak fluctuations go, Immunocore Holdings' EBT Margin surged by 5684600bps in 2022, and later plummeted by -108600bps in 2023.
  • Over the past 5 years, Immunocore Holdings' EBT Margin (Quarter) stood at 594.15% in 2021, then surged by 96bps to 25.68% in 2022, then tumbled by -42bps to 36.55% in 2023, then grew by 19bps to 29.53% in 2024, then skyrocketed by 101bps to 0.29% in 2025.
  • Its EBT Margin stands at 0.29% for Q3 2025, versus 9.9% for Q2 2025 and 6.48% for Q1 2025.